| 1 |
B. Prodic-Kojic, Study on crystalline forms of N-cyano-N`methyl- N'- (2([(4-methyl-lH-imidazol-5-yl)methyl]thio)ethyl) guanidine (cimetidine), Gazzetta Chimica Italiana, 109, 535-539 (1979).
|
| 2 |
A Chauvet, R. Perrier and l Masse, Etude thermoanalytique de quelques steroides. I. testosterone et derives, Thermochimica Acta, 43, 161-172 (1981)
DOI
ScienceOn
|
| 3 |
E. Smakula, A Gari and H.H. Wotiz, Effects of polymorphism and influence of sample preparation on the infra-red spectrum of estradiol-17 , Spectrochimica Acta, 9, 346-356 (1957)
DOI
ScienceOn
|
| 4 |
A. Burger and U.I. Griesser, Charakterisierung und Identifizierung von 11 Kristallformen von Succinylsulfathiazol, Sci. Pharm., 57, 293-305 (1989)
|
| 5 |
A. Burger and R.D. Dialer, Neue Untersuchungsergebnisse von Polymorphie von Sulfathiazol, Pharm. Acta Helv., 58, 72-78 (1983)
|
| 6 |
A. Burger, K. Schulte and R. Ramberger, Autklaerung thermodynamischer Beziehungen zwischen fuenf polymorphen Modifikationen von Sulfapyridin mittel DSC, J. Therm. Anal., 19, 475-484 (1980)
DOI
|
| 7 |
M.A. Moustafa, A.R. Ebian, S.A. Khalil and M.M. Motawi, Sulfamethoxydiazine crystal forms, J. Pharm. Phannacol., 23, 868-874 (1971)
|
| 8 |
H.O. Lin, N.C. Baenziger and lK Guillory, Physical properties of four polymorphic forms of sulfanilamide I: Densities, refractive indexes, and X-ray diffraction measurements, J. Pharm. sci., 63, 145-146 (1974)
DOI
|
| 9 |
E.G. Shami, P.D. Bernardo, E.S. Rattie and L.I. Ravin, Kinetics of polymorphic transformation of sulfathiazol form I, J. Pharm. Sci., 61, 1318-1320 (1972)
DOI
|
| 10 |
L.S. Shenouda, Various species of sulfathiazol form I, J. Pharm. Sci., 59, 785-787 (1970)
DOI
|
| 11 |
A.R. Ebian, M.A. Moustafa, S.A. Khalil and M.M. Motawi, Succinylsulfathiazol crystal forms II: effect of additives on kinetics of interconversion, J. Pharm. Sci., 64, 1481-1481 (1975)
DOI
|
| 12 |
M. Janik, Z. Malarski, J. Mrozinski, l Wajcht and Z. Zborucki, Influence of solvent effect on polymorphism of 4hydroxy- 2-methyl-N-2-pyridy1-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide (piroxicam), J. Crystallogr. Spec. Res., 21, 519-522 (1991)
DOI
|
| 13 |
B. Kojic-Prodic and Z. Ruzic-Toros, Structure of the antiinflammatory drug 4-hydroxy-2-methyl-N-2-pyridyl-2H1,2- benzothiazine-3-carboxamide-1,1-dioxide (piroxicam), Acta Crystallogr., B38, 2948-2951 (1982)
|
| 14 |
M. Shibata, H. Kokubo, K Morimoto, K Morisaka, T. Ishida and M. Inoue, X-ray structural studies and physicochemical properties of cimetidine polymorphism, J. Pharm. Sci., 72, 1436-1442 (1983)
DOI
|
| 15 |
A. Bauer-Brandl and Y.T. Sohn, Crystal modifications of cimetidine: characterization and evaluation for manufacturing of dosage forms, Eur. J. Pharm. Biopharm., 40(Suppl.), 6S (1994)
|
| 16 |
Y.T. Sohn and K.S. Kim, Study on polymorphism of cimetidine, J. Kor. Pharm. Sci., 23, 81-87 (1993)
|
| 17 |
M. Kuhnert-Brandstaetter and H. Winkler, Thermoanalytische und IR-spektroskopische Untersuchungen an verschiedenen Kristallformen von Arzneistoffen aus der Oestradiol- und Androstangruppe, Sci. Pharm., 44, 288-299 (1976)
|
| 18 |
AT. Florence and E.G. Salole, Changes in crystallinity and solubility on comminution of digoxin and observations on spironolactone and oestradiol, J. Pharm. Phanncol., 28, 637-642 (1976)
DOI
|
| 19 |
M. Muramatsu, M. Iwahashi and U. Takeuchi, Thennodynamic relationship between   of crystalline progesterone, J. Pharm. Sci., 68, 175-177 (1979)
DOI
|
| 20 |
J.K Haleblian, R.T. Koda and lA Biles, Isolation and characterization of some solid phases of fluprednisolone, J. Pharm. Sci., 60, 1485-1488 (1971)
DOI
|
| 21 |
J.W. Poole and C.K. Bahal, Dissolution Behavior and solubility of anhydrous and trihydrate forms of ampicillin, J. Pharm. Sci., 57, 1945-1948 (1968)
DOI
|
| 22 |
M.C. Tros de llarduya, C. Martin, M.M. Goni and M.C. Martinez-Uharriz, Dissolution rate of polymorphs and two new pseudopolymorphs of sulindac, Drug Dev. Ind. Pharm., 23, 1095-1098 (1997)
DOI
ScienceOn
|
| 23 |
H.G. Ibrahim, F. Pisano and A Bruno, Polymorphism of phenylbutazone: properties and compressional behavior of crystals,. Pharm. Sci., 66, 669-673 (1977)
DOI
|
| 24 |
M.D. Tuladhar, J.E. Carless and M.P. Summers, The effects of polymorphism, particle size and compression pressure on the dissolution rate of phenylbutazone tablets, J. Pharm. Pharmacol., 35, 269-274 (1983)
DOI
|
| 25 |
M.D. Tuladhar, J.E. Carless and M.P. Summers, Thermal behavior and dissolution properties of phenylbutazone polymorphs, J. Pharm. Pharmacol., 35, 208-214 (1983)
DOI
|
| 26 |
J. Matsunaga, N. Nambu and T. Nagai, Polymorphism of phenylbutazone, Chern. Pharm. Bull., 24, 1169-1172 (1976)
DOI
ScienceOn
|
| 27 |
Y.T. Sohn and E.H. Lee, Crystal form of cephazoline sodium hydrate, Yakhak Hoeji, 40, 306-310 (1996)
|
| 28 |
Y.T. Sohn and I.J. Chun, Crystal form of cefaclor, J. Kor Phann. Sci., 30, 201-206 (2000)
|
| 29 |
J. Bordner, J.A. Richards, P. Weeks and E.B. Whipple, Piroxicam monohydrate: a zwitterionic form  , Acta Crystallogr., C40, 989-990 (1984).
|
| 30 |
Y.T. Sohn and S.Y Kim, Study on polymorphism of cephalexin, Duksung Bull. Pharm. Sci., 7, 1-8 (1996)
|
| 31 |
G.A .Ghan and J.K Lalla, Effect of compressional forces on piroxicam polymorphs, J. Pharm. Pharmacol., 44, 678-681 (1992)
DOI
|
| 32 |
E. Rasanen, J. Rantanen, A. Jorgensen, M. Karjalainen, T. Paakkari and J. Yliruusi, Novel identification of pseudopolymorphic changes of theophylline during wet granulation using near infrared spectroscopy, J. Pharm. Sci., 90, 389-396 (2001)
DOI
ScienceOn
|
| 33 |
M. Kuhnert-Brandstaetter and R Voellenklee, Thermoanalytische und IR-spektroscopische Untersuchungen an polymorphen Arzneistoffen: Acemetacin, Piroxicam, Propranolohydrochlorid und Urapidil, Frasenius Z. Anal. Chem., 322, 164-169 (1985)
DOI
|
| 34 |
M. Mihalic, H. Hofman, F. Kafez, J. Kuftinec, N. Blazvic and M. Zinic, Physico-chemical and analytical characteristics of piroxicam, Acta Phann. Jugosl., 32, 13-20 (1982)
|
| 35 |
G. Reck, G. Dietz, G. Laban, W Guenther, G. Banier and E. Hoehne, X-ray studies on piroxicam modifications, Phannazie, 43, 477-481 (1988)
|
| 36 |
G. Reck and G. Laban, Prediction and establishment of a new crystalline piroxicam modification, Phannazie, 45, 257-259 (1990)
|
| 37 |
F. Vrecer, S. Srcic and J. Smid-Korbar, Investigation of piroxicam polymorphism, Int. J. Pharm., 68, 35-41 (1991)
DOI
ScienceOn
|
| 38 |
A. Burger and A. Lettenbichler, Polymorphie und Pseudopolymorphie von Acemetacin, Phannazie, 48, 262-272 (1993)
|
| 39 |
E. Shefter and T. Higuchi, Dissolution behavior of crystalline solvated and nonsolvated forms of some pharmaceuticals, J. Pharm. Sci., 52, 781-791 (1963)
DOI
|
| 40 |
M. Kuhnert-Brandstaetter and G. Lehner, Differentialthermoanalytische und IR-spektroskopische Untersuchungen von Arzneistoffen, die als Hydrate vorliegen, Sci. Pharm., 52, 267-279 (1984)
|
| 41 |
D.Q.M. Craig, P.G. Royall, Y.L. Kett and M.L. Hopton, The relevance of the amorpous state to pharmaceutical dosage forms: Glassy drugs and freeze dried systems., Int. J. Pharm., 179, 179-207 (1999)
DOI
ScienceOn
|
| 42 |
M.U.A. Ahlqvist and L.S. Taylor, Water diffusion in hydrated crystalline and amorphous sugars monitored using HID exchange, J. Pharm. Sci., 91, 690-698 (2002)
DOI
ScienceOn
|
| 43 |
M.C. Tros de Ilarduya, C. Martin, M.M. Goni and M.C. Martinez-Oharriz, Polymorphism of sulindac: Isolation and characterization of a new polymorph and three new solvates, J. Pharm. Sci., 86, 248-251 (1997)
DOI
ScienceOn
|
| 44 |
Z. Dong, B.E. Padden, J.S. Salsbury, EJ. Munson, SA Schroeder, I. Prakash and DJ.W Grant, Neotame anhydrate polymorphs I: Preparation and characterization, Pharm. Res., 19, 330-336 (2002)
DOI
ScienceOn
|
| 45 |
A.K. Dash, Y. Mo and A Pyne, Solid-state properties of creatine monohydrate, J. Pharm. Sci., 91, 708-718 (2002)
DOI
ScienceOn
|
| 46 |
S. Ito, M. Nishimura, Y. Kobayashi, S. Itai and K. Yamamoto, Characterization of polymorphs and hydrates of GL-128, a serotonin3 receptor antagonist, Int. J. Pharm., 151, 133-143 (1997)
DOI
ScienceOn
|
| 47 |
H. Zhu and DJ. W Grant, Dehydration behavior of nedocromil magnesium pentahydrate, Int. J. Pharm., 215, 251-262 (2001)
DOI
ScienceOn
|
| 48 |
A. Jorgensen, J. Rantanen, M. Karjalainen, L. Khriachtchev, E. Rasanen and J. Yliruusi, Hydrate formation during wet granulation studied by spectroscopic methods and multivariate analysis, Pharm. Res., 19, 1285-1291 (2002)
DOI
ScienceOn
|
| 49 |
S.Y. Lin and J.L. Chien, In vitro simulation of solid-solid dehydration, rehydraton, and solidification of trehalose dihydrate using thermal and vibrational spectroscopic techniques, Pharm. Res., 20, 1926-1931 (2003)
DOI
ScienceOn
|
| 50 |
Z. Dong, J.S. Salsbury, D. Zhou, EJ. Munson, SA Schroeder, I. Prakash, S. Vyazovkin, C.A Wight and DJ.W Grant, Dehydration kinetics of Neotame monohydrate, J. Pharm. Sci., 91, 1423-1431 (2002)
DOI
ScienceOn
|
| 51 |
RG. Brittain, Fluorescence studies of the transformation of carbamazepine anhydrate form III to its dihydrate phase, J. Pharm. Sci., 93, 375-383 (2004)
DOI
ScienceOn
|
| 52 |
N. Rodriguez-Hornedo and D. Murphy, Surfactant-facilitated crystallization of dihydrate carbamazepine during dissolution of anhydrous polymorph, J. Pharm. Sci., 93, 449-460 (2004)
DOI
ScienceOn
|
| 53 |
N. Rodriguez-Hornedo and D. Murphy, Surfactant-facilitatedn crystallization of dihydrate carbamazepine during dissolution of anhydrous polymorph, J. Pharm. Sci., 93, 449-460 (2004)
DOI
ScienceOn
|
| 54 |
L.S. Taylor and P. York, Characterization of the phase transitions of trehalose dihydrate on heating and subsequent dehydration, J. Pharm. Sci., 87, 347-355 (1998)
DOI
ScienceOn
|
| 55 |
E.C. van Tonder, T.S.P. Maleka, W Liebenberg, M. Song, D.E. Wurster and M.M. de Villiers, Preparation and physicochemical properties of niclosarnide anhydrate and two monohydrates, Int. J. Pharm., 269, 417-432 (2004)
DOI
ScienceOn
|
| 56 |
L.R. Hilden and K.R. Morris, Physics of amorphous solids, J. Pharm. Sci., 93, 3-12 (2004)
DOI
ScienceOn
|
| 57 |
B.C. Hancock and G. Zografi, Characteristics and significance of the amorphous state in pharmaceutical systems, J. Pharm. Sci., 86, 1-12 (1997)
DOI
ScienceOn
|
| 58 |
L. Yu, Amorphous pharmaceutical solids. Preparation, characterization and stabilization, Adv. Drug Del. Rev., 48, 27-42 (2001)
DOI
ScienceOn
|
| 59 |
I. Nikolakakis, K. Kachrimanis and S. Malamataris, Relations between crystallisation conditions and micromeritic properties of ibuprofen, Int. J. Pharm., 201, 79-88 (2000)
DOI
ScienceOn
|
| 60 |
X.C. Tang, MJ. Pikal and L.S. Taylor, The effect of temperature on hydrogen bonding in crystalline and amorphous phases in dihydropyrine calcium channel blockers, Pharm. Res., 19, 484-490 (2002)
DOI
ScienceOn
|
| 61 |
X.C. Tang, MJ. Pikal and L.S. Taylor, A spectroscopic investigation of hydrogen bond patterns in crystalline and amorphous phases in dihydropyrine calcium channel blockers, Pharm. Res., 19, 477-483 (2002)
DOI
ScienceOn
|
| 62 |
N. Boutonnet-Fagegaltier, J. Menegotto, A Lamure, R Duplaa, A Caron, C. Lacabanne and M. Bauer, Molecular mobility study of amorphous and crystalline phases of a pharmaceutical product by thermally stimulated current spectrometry, J. Pharm. Sci.,91, 1548-1560 (2002)
DOI
ScienceOn
|
| 63 |
A. Pyne, K. Chatterjee and R Suryanarayanan, Crystalline to amorphous transition of disodium hydrogen phosphate during primary drying, Pharm. Res., 20, 802-803 (2003)
DOI
ScienceOn
|
| 64 |
J. Haleblian, Characterization of habits and crystalline modification of solids and their phannaceutical applications, J. Pharm. Sci., 64, 1269-1288 (1975)
DOI
|
| 65 |
Y. Aso, S. Yoshioka and S. Kojima, Explanation of the crystallization rate of amorphous nifedipine and phenobarbital from their molecular mobility as measured by 13C nuclear magnetic resonance relaxation time and the relaxation time obtained from the heating rate dependence of the glass transition temperature, J Pharm. Sci., 90, 798-806 (2001)
DOI
ScienceOn
|
| 66 |
T. Yoshinari, R.T. Forbes, P. York and Y. Kawashima, Crystallisation of amorphous mannitol is retarded using boric acid, Int. J. Pharm., 258, 109-120 (2003)
DOI
ScienceOn
|
| 67 |
R. Surana, A. Pyne and R. Suryanarayanan, Effect of agingn on the physical properties of amorphous trehalose, Pharm. Res., 21, 867-874 (2004)
DOI
ScienceOn
|
| 68 |
R. Price and P.M. Young, Visualization of the crystallization of lactose from the amorphous state, J Pharm. Sci., 93, 155-64 (2004)
DOI
ScienceOn
|
| 69 |
Y. Aso, S. Yoshioka and S. Kojima, Explanation of the crystallization rate of amorphous nifedipine and phenobarbital from their molecular mobility as measured by  .nuclear magnetic resonance relaxation time and the relaxation time obtained from the heating rate dependence of the glass transition temperature, J Pharm. Sci., 90, 798-806 (2001)
DOI
ScienceOn
|
| 70 |
C. Telang, L. Yu and R. Suryanarayanan, Effective inhibition of mannitol crystallization in frozen solutions by sodium chloride, Pharm. Res., 20, 660-667 (2003)
DOI
ScienceOn
|
| 71 |
D. Kaul, N.T. Nguyen and S. Venkataram, Crystal habit modifications and altered tableting characteristics, Int. J. Pharm., 88, 345-350 (1992)
DOI
ScienceOn
|
| 72 |
A. Nokhodchi, N. Bolourtchian and R. Dinarvand, Crystal modification of phenytoin using different solvents and crystallization conditions, Int. J. Pharm., 250, 85-97 (2003).
DOI
ScienceOn
|
| 73 |
A.H.L. Chow, P.K.K. Chow, Z. Wang and D.G.W. Grant, Modifications of acetaminophen crystals: influence of growth in aqueous solutions containing p-acetoxyacetanilide on crystal properties, Int. J Pharm., 24, 239-258 (1985)
DOI
ScienceOn
|
| 74 |
M.N. Femi-Oyewo and M.S. Spring, Studies on paracetamol crystals produced by growth in aqueous solutions, Int. J Pharm., 112, 17-28 (1994)
DOI
ScienceOn
|
| 75 |
J.W. Shell, X-ray and crystallographic applications in pharmaceutical research III. crystal habit quantitation, J. Pharm. Sci., 52, 100-101 (1963).
DOI
|
| 76 |
A. Saleki-Gerhardt and G. Zografi, Non-isothermal and isothermal crystallization of sucrose from the amorphous state, Pharm. Res., 11, 1166-1173 (1994)
DOI
ScienceOn
|
| 77 |
N. Rodriguez-Hornedo and D. Murphy, Significance of controlling crystallization mechanisms and kinetics in pharmaceutical systems, J Pharm. Sci., 88, 651-660 (1999)
DOI
|
| 78 |
MS.L. Price, The computational prediction of pharmaceuticaln crystal structures and polymorphism, Advanced Drug Delivery Reviews, 56, 301-319 (2004)
DOI
ScienceOn
|
| 79 |
P.V. Marshall and P. York, Crystallization solvent induced solid-state and particulate modifications of nitrofurantoin, Int. J Pharm., 55, 257-263 (1989)
DOI
ScienceOn
|
| 80 |
K.V.R Prasad, R.I. Ristic, D.B. Sheen and J.N. Sherwood, Crystallization of paracetamol from solution in the presence and absence of impurity, Int. J. Pharm., 215, 29-44 (2001).
DOI
ScienceOn
|
| 81 |
P.Y. Marshall and P. York, The compaction properties of nitrofurantoin samples crystallised from different solvents, Int. J. Pharm., 67, 59-65 (1991)
DOI
ScienceOn
|
| 82 |
HA Garekani, J.L. Ford, M.H. Rubinstein and A.R. Rajabi-Siahboom,i, Formation and compression characteristics of prismatic polyhedral crystal and thin plate like crystals of paracetamol, Int. J Pharm., 187, 77-89 (1999)
DOI
ScienceOn
|
| 83 |
T. Oguchi, N. Sasaki, T. Hara, Y. Tozuka and K. Yamamoto, Differential thermal crystallization from amorphous chenodeoxycholic acid between the ground specimens derived from the polymorphs, Int. J Pharm., 253, 81-88 (2003)
DOI
ScienceOn
|
| 84 |
B. Bachet, X-ray characterization of the triclinic polymorph of carbamazepine, J Pharm. Sci., 86, 1062-1065 (1997)
DOI
ScienceOn
|
| 85 |
M.M.J. Lowes, M.R. Caira, A.P. Lotter and J.G. van der Watt, Physicochemical properties and X-ray structural studies of the trigonal polymorph of carbarnazepine, J. Pharm. Sci., 76, 744-752 (1987).
DOI
|
| 86 |
P.J. Cox and J.L. Wardell, Studies of polymorphism in three compounds by single crystal X-ray diffraction, Int. J. Pharm., 194, 147-153 (2000)
DOI
ScienceOn
|
| 87 |
S. Yamamura and Y Momose, Quantitative analysis of crystalline pharmaceuticals in powders and tablets by a pattem-fitting procedure using X-ray powder diffraction data, Int. J .Pharm., 212, 203-212 (2001).
DOI
ScienceOn
|
| 88 |
J.D. Gordon and A.H.L. Chow, Modification of phenytoin crystals: influence of 3-propanoyloxymethyl-5, 5-diphenylhydantoin on solution-phase crystallization and related crystal properties, Int. J Pharm., 79, 171-181 (1992)
DOI
ScienceOn
|
| 89 |
K. Kachrimanis, G. Ktistis and S. Malamataris, Crystallization conditions and physicochemical properties, of ibuprofen-Eudragit Sl100 spherical crystal agglomerates prepared by the solvent-change technique, Int. J. Pharm., 173,61-74 (1998)
DOI
ScienceOn
|
| 90 |
HA Garekani, J.L. Ford, M.H. Rubinstein and AR Rajabi-Siahboomi, Highly compressible paracetamol: crystallization and characterization, Int. J Pharm., 208, 8799 (2000)
|
| 91 |
J. Haleblian and W. McCrowne, Pharmaceutical applications of polymorphism, J Pharm. Sci., 58, 911-929 (1969)
DOI
|
| 92 |
A,S, Raw, M.S. Furness, D.S. Gill, R.C. Adams, F.O. Holcombe Jr. and L.X. Yu, Regulatory considerations of pharmaceutical solid polymorphism in abbreviated new drug applications (ANDA), Advanced Drug Delivery Reviews, 56, 397-414 (2004)
DOI
ScienceOn
|
| 93 |
G.L. Perlovich, L.Kr. Hansen and A. Bauer-Brandl, Interrelation between thermochemical and structural data of polymorphs exemplified by diflunisal, J. Pharm. Sci., 91, 1036-1045 (2001).
DOI
ScienceOn
|
| 94 |
S.L. Wang, S.Y Lin and YS. Wei, Transformation of metastable forms of acetaminophen studied by thermal Fourier transform Infrared (FT-IR) microspectroscopy, Chem. Pharm. Bull., 50, 153-156 (2002)
DOI
ScienceOn
|
| 95 |
M. Blanco and A Villar, Development and validation of a method for the polymorphic analysis of pharmaceutical preparations using near infrared spectroscopy, J. Pharm. Sci., 92, 823-830 (2003).
DOI
ScienceOn
|
| 96 |
J.P Higgins, S.M. Arrivo and RA Reed, Approach to the determination of hydrate form conversions of drug compounds and solid dosage forms by near-IR spectroscopy, J. Pharm. Sci., 92, 2303-2316 (2003)
DOI
ScienceOn
|
| 97 |
R Huettenrauch, Fundamentals of Pharmaceutics, Acta Phann. Technol., 34, 1-10 (1988)
|
| 98 |
A. Gruenenberg, Polymorphie und thermische Analyse pharmazeutischer Wrrkstoffe, Phannazie in unserer Zeit, 26, 224-231 (1997)
DOI
ScienceOn
|
| 99 |
YH. Kiang, A Huq, P.W. Stephens and W. Xu, Structure determination of enalapril maleate form II from HighResolution X-ray powder diffraction data, J Pharm. Sci., 92, 1844-1853 (2003)
DOI
ScienceOn
|
| 100 |
R. Suryanarayanan, Determination of the relative amounts of anhydrous carbamazepine( ) and carbamazepine dihydrate( ) in a mixture by powder X-ray diffractometry, Pharm. Res., 6, 1017-1024 (1989)
DOI
ScienceOn
|
| 101 |
G.G.Z. Zhang, e. Gu, M.T Zell, R.T. Burkahardt, E.J. Munson and D.J.W. Grant, Crystallization and transitions of sulfamerazine polymorphs, J. Pharm. Sci., 91, 1089-1100 (2002).
DOI
ScienceOn
|
| 102 |
T.D. Davis, G.E. Peck, J.G. Stowell, K.R. Morris and S.R. Bym, Modeling and monitoring of polymorphic transformations during the drying phase of wet granulation, Pharm. Res., 21, 860-866 (2004).
DOI
ScienceOn
|
| 103 |
S. Yada, M. Ohya, Y Ohuchi, T Hamaura, N. Wakiyama, F. Usui, A Kusai and K Yamamoto, Solid phase transition of CS-891 enantiotropes during grinding, Int. J. Pharm., 255, 69-79 (2003)
DOI
ScienceOn
|
| 104 |
S. Rastogi, M. Zakrzewski and R. Suryanarayanan, Investigation of solid-state reactions using variable temperature X-ray powder diffractometry. I. Aspartame hemihydrate, Pharm. Res., 18, 267-273 (2001)
|
| 105 |
S.K. Rastogi, M. Zakrzewski and R Suryanarayanan, Investigation of solid-state reactions using variable temperature X-ray powder diffractometry. II. Aminophylline monohydrate, Pharm. Res., 19, 1265-1273 (2002)
DOI
ScienceOn
|
| 106 |
D. Giron, Thermal analysis and calorimetric methods in the characterization of polymorphs and solvates, Thermochim Acta, 248, 1-59 (1995)
DOI
ScienceOn
|
| 107 |
N. Ohnishi, T. Yokoyama and K. Kuroda, Isothermal transition of polymorphic forms of some drugs, Phann. Tech. Japan, 3, 355-360 (1987)
|
| 108 |
Y.T. Sohn and B.Y. Urn, Dissolution of crystal form of glibenclamide, J. Kor. Pharm. Sci., 27, 233-239 (1997)
|
| 109 |
H.H.Y Tong, B. Yu. Shekunov, P. York and A,H,L. Chow, Thermal analysis of trace levels of polymorphic impurity in salmeterol xinafoate samples, Pharm. Res., 20, 1423-1429 (2003)
DOI
ScienceOn
|
| 110 |
Y.T. Sohn and S.H. Park, Effects of crystal modification of cephalothin sodium on dissolution and stability, Yakhak Hoeji, 41, 321-327 (1997)
|
| 111 |
Y.T. Sohn and H.K. Kim, Dissolution of crystal form of cephotaxime sodium, J. Kor. Pharm. Sci., 28, 81-85 (1998)
|
| 112 |
Y.T. Sohn and J.S. Kim, Effect of crystal form on dissolution of cephradin, J. Kor. Pharm. Sci., 28, 115-119 (1998).
|
| 113 |
Y.T. Sohn and E.S. Do, Effect of crystal form on dissolution of prednisolone, J. Kor. Pharm. Sci., 33, 99-103 (2003)
|
| 114 |
A.D. Patel, P.E. Luner and M.S. Kemper, Low-level determination of polymorph composition in physical mixtures by near-infrared reflectance spectroscopy, J. Pharm. Sci., 90, 360-370 (2001).
DOI
ScienceOn
|
| 115 |
A.D. Patel, P.E. Luner and M.S. Kemper, Quantitative analysis of polymorphs in binary and multi-component powder mixtures by near-infrared reflectance spectroscopy, Int. J. Pharm., 206, 63-74 (2000).
DOI
ScienceOn
|
| 116 |
R Suryanarayanan and T.S. Wiedmann, Quantitation of the relative amounts of anhydrous carbamazepine () and carbamazepine dihydrate () in a mixture by solid-state nuclear magnetic resonance(NMR), Pharm. Res., 7, 184-187 (1990)
DOI
ScienceOn
|
| 117 |
A Gruenenberg, Poymorphie und Thermische Analyse pharmazeutischer Wirkstoffe, Pharmazie in unserer Zeit, 26, 224-231 (1997)
DOI
ScienceOn
|
| 118 |
M. Kuhnert-Brandstaetter and A. Burger, Untersuchungen zum Aufloesungsverhalten polymorpher, pseudopolymorpher und amorpher Phasen von Arzneimitteln, Pharm. Ind., 34, 187-190 (1972).
|
| 119 |
H. Junginger, Modifikationsumwandlungen dmch mechanische Bearbeitung, Pharm. Ind., 39, 68-71 (1977)
|
| 120 |
Y.T. Sohn and S.Y. Kim, Effect of crystal form on in vivo topical anti-inflammatory activity of corticosteroids, Arch. Pharm. Res., 25, 556-559 (2002)
DOI
ScienceOn
|
| 121 |
Y.T. Sohn, Pharmaceutical application of polymorphism, Pharmacon, 21, 500-516 (1991)
|
| 122 |
L. Borka, Review on crystal polymorphism of substances in the European Pharmacopoeia (Fasculae 1 to 12), Part 1, Pharmeur., 7, 574-585 (1995)
|
| 123 |
K. Urakami and A.E. Beezer, A kinetic and thermodynamic study of seratrodast polymorphic transition by isothermal microcalorimetry, Int. J. Pharm., 257, 265-271 (2003)
DOI
ScienceOn
|
| 124 |
C. Sun and DJ.W. Grant, Influence of crystal structure on the tableting properties of sulfamerazine polymorphs, Pharm. Res., 18, 274-280 (2001)
DOI
ScienceOn
|
| 125 |
T. Yoshinari, R.T. Forbes, P. York and Y. Kawashima, The improved compaction properties of mannitol after a moistureinduced polymorphic transition, Int. J. Pharm., 258, 121-131 (2003).
DOI
ScienceOn
|
| 126 |
M. Mirmehrabi, S. Rohani, K.S. Keshava Murthy and B. Radatus, Improving the filterability and solid density of ranitidine hydrochloride form 1, J. Pharm. Sci., 93, 1692-1700 (2004)
DOI
ScienceOn
|
| 127 |
S. Roy, K.S. Alexander, A.T. Riga and K Chatterjee, Characterization of physical mixtures and directly compressed tablets of sulfamerazine polymorphs: Implications on in vitro release characteristics, J. Pharm. Sci., 92, 747-759 (2003)
DOI
ScienceOn
|
| 128 |
Y.T Sohn and S.H. Jung, Effect of crystal form on dissolution and stability of droperidol, Yakhak Hoeji, 40, 375-381 (1996)
|
| 129 |
Y.T. Sohn, Dissolution and transformation of crystal form of piroxicam, Yakhak Hoeji, 40, 513-521 (1996)
|
| 130 |
B. Hegedues andS. Georg, The polymorphism od cimetidine, J Phann. Biomed. Anal., 3, 303-307 (1985)
DOI
ScienceOn
|
| 131 |
Y. Yoshihashi, H. Kitano, E. Yonemochi and K. Terada, Quantitative correlation between initial dissolution rate and heat of fusion of drug substance, Int. J. Pharm., 204, 1-6 (2000)
DOI
ScienceOn
|
| 132 |
A.J. Aguiar, J. Krc jun, A.W. Kinkel and Ie. Samyn, Effect of polymorphism on the absorption of chloramphenicol from chloramphenicol palmitate, J. Pharm. Sci., 56, 847-853 (1967)
DOI
|
| 133 |
G. Opalchenova and G.N. Kalinkova, Evaluation of a new polymorph aziocillin sodium by its antibacterial activity, Int. J. Pharm., 153, 263-265 (1997)
DOI
ScienceOn
|
| 134 |
Y. Kobayashi, S. Ito, S. Itai and K. Yamamoto, Physicochemical properties and bioavailability of carbamazepine polymorphs and dihydrate, Int. J. Pharm., 193, 137-146 (2000)
DOI
ScienceOn
|
| 135 |
Y.T. Sohn, Effect of polymorphism on bioavailability of amoxycillin, Yakhak Hoeji, 39, 438-443, (1995)
|
| 136 |
Y.T. Sohn, Study on polymorphism of sulfa drugs, J. Kor. Pharm. sci., 20, 35-42 (1990)
|
webmaster
